APN/CD13 inhibitor Ubenimex: A molecular chaperone of antineoplastic chemotherapeutic drugs
10.3969/j.issn.1001-1978.2021.11.004
- Author:
Yu-Qian MA
1
;
Xiao-Yan XING
1
;
Bin-Bin GE
1
;
Yu-Tian LI
1
;
Wen-Yan JIANG
1
;
Hai-Yong JIA
1
;
Xue-Jian WANG
1
;
Wen-Fang XU
2
Author Information
1. Weifang Medical University
2. Qingdao Marine Biomedical Research Institute
- Publication Type:Journal Article
- Keywords:
aminopeptidase N;
anti-tumor;
cytotoxic drugs;
reversing drug resistance;
Ubenimex
- From:
Chinese Pharmacological Bulletin
2021;37(11):1497-1502
- CountryChina
- Language:Chinese
-
Abstract:
Cytotoxic anti-neoplastic drugs are a kind of chemotherapeutic drugs that directly kill or inhibit the growth and proliferation of tumor cells, and it is one of the main drugs for the treatment of malignant tumors. These drugs may have toxic side effects on normal cells of human body (especially those with strong division and proliferation) when they are used to kill tumor cells. And patients may usually have adverse reactions even at a normal dose when using this kind of drugs. Due to the strong toxic side effects of cytotoxic chemotherapeutic drugs, their clinical application is limited. In recent years it has been found that aminopeptidase N inhibitor Ubenimex has a significant synergistic effect with anti-neoplastic chemotherapeutic drugs, which has the advantages of enhancing the therapeutic effect of drugs and reducing the toxic side effects of chemotherapeutic drugs. This review enumerates that the combination of Ubenimex and a variety of cytotoxic drugs can enhance the anti-tumor effect of cytotoxic drugs and reduce the occurrence of adverse reactions. In addition, the mechanism of combined use of Ubenimex in reversing drug resistance is also introduced. At the same time, is is further confirmed the clinical value of Ubenimex as an effective adjuvant in the treatment of malignant tumors, so as to provide a basis for clinical application.
